Hyperphosphatemia treatment agent

A technology for hyperphosphatemia and therapeutic agent, applied in the field of hyperphosphatemia therapeutic agent, can solve problems such as decreased medication compliance, and achieve the effect of improving life prognosis

Pending Publication Date: 2020-06-02
FUJIFILM CORP +1
View PDF17 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0002] Chronic kidney disease (CKD) patients and dialysis patients are mostly under multi-dose prescriptions and medication adherence tends to be reduced

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Hyperphosphatemia treatment agent
  • Hyperphosphatemia treatment agent
  • Hyperphosphatemia treatment agent

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1-1

[0271] 400 g of a 15.0 mass % polyallylamine aqueous solution (PAA-15C manufactured by Nittobo Medical Co., Ltd., amine value: 17.5 mmol / g) was distilled off under reduced pressure to prepare 150 g of a 40.0 mass % polyallylamine aqueous solution (first solution ).

[0272] 318 g of a second solution was prepared by dissolving 15.0 g of ethyl cellulose (Ethyl cellulose (approximately 49% ethoxylated) 45 manufactured by Wako Pure Chemical Industries, Ltd., weight average molecular weight: 125,000) in 303 g of toluene.

[0273] The above-mentioned first solution and the above-mentioned second solution were mixed in a 500 mL separable flask equipped with a Dean-Stark apparatus, thereby obtaining a mixture. Using stainless steel flat stirring blades (IKA R1375, blade diameter 70 mm) and Shinto Science Co., Ltd. Three-One Motor (BL600), the above mixture was stirred at 60° C. at 120 rpm for 60 minutes, by This gives a polyallylamine emulsion. Table 1 describes the physical proper...

Embodiment 2

[0286] 180 g of a 40.0 mass % polyallylamine aqueous solution (the first solution ).

[0287] 382 g of a second solution was prepared by dissolving 18.0 g of ethyl cellulose (Ethyl cellulose (approximately 49% ethoxylated) 45 manufactured by Wako Pure Chemical Industries, Ltd., weight average molecular weight: 125,000) in 364 g of toluene.

[0288] The above-mentioned first solution and the above-mentioned second solution were mixed in a 500 mL separable flask equipped with a Dean-Stark apparatus, thereby obtaining a mixture. Using stainless steel flat stirring blades (IKA R1375, blade diameter 70mm) and Shinto Science Co., Ltd. Three-One Motor (BL600), the above mixture was stirred at 50° C. at 120 rpm for 60 minutes. This gives a polyallylamine emulsion.

[0289] To the obtained emulsion, a solution obtained by diluting 4.90 g of 1,6-dichlorohexane (manufactured by Tokyo Chemical Industry Co., Ltd.) with 12 mL of toluene was added dropwise over 10 minutes. After completio...

Embodiment 3

[0291] Except having changed the temperature at the time of stirring from 50 degreeC to 80 degreeC, it carried out similarly to Example 2, and obtained the crosslinked polyallylamine spherical particle.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention addresses the problem of providing a low-dose hyperphosphatemia treatment agent that can substantially reduce serum phosphorus concentration. The present invention provides a hyperphosphatemia treatment agent that contains, as an active ingredient, particles that include a prescribed crosslinked polymer (preferably crosslinked polyallylamine).

Description

technical field [0001] The present invention relates to a therapeutic agent for hyperphosphatemia comprising particles containing a crosslinked polymer as an active ingredient. Background technique [0002] Patients with chronic kidney disease (CKD) and dialysis patients are mostly under multi-dose prescriptions, and medication adherence tends to be reduced. Decreased adherence to polymer-based phosphorus-adsorbing drugs, the most frequently administered drug, was associated with high serum phosphorus levels, high parathyroid hormone (PTH) values, and decreased quality of life (QOL). The decrease in compliance is also caused by the dose of the drug (for example, refer to Non-Patent Document 1). [0003] As phosphorus-adsorbing drugs for the treatment of hyperphosphatemia in CKD patients and dialysis patients, metal-based phosphorus-adsorbing drugs such as calcium carbonate and lanthanum carbonate are used, and sevelamer hydrochloride and bixalomer are also used. ) and othe...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/785A61P3/00A61P13/12
CPCA61K31/785A61P3/00A61P13/12
Inventor 德冈伸介吉田隼人近藤雄一朗
Owner FUJIFILM CORP
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap